 In 2004, Schinazi was one of the founders of Pharmasset, a company that would later go on to develop sofosbuvir.The name Pharmasset was derived from 'pharmaceutical assets' and the original business plan was to create assets that would be sold to other companies.The company raised around $45M in its 2007 IPO at $9 per share.